vs
CITIZENS FINANCIAL SERVICES INC（CZFS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CITIZENS FINANCIAL SERVICES INC的1.0倍（$30.3M vs $29.6M），CITIZENS FINANCIAL SERVICES INC净利率更高（35.4% vs -221.3%，领先256.7%），REGENXBIO Inc.同比增速更快（43.0% vs 13.0%），CITIZENS FINANCIAL SERVICES INC自由现金流更多（$35.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 6.9%）
公民金融集团是一家美国银行控股公司，总部位于罗得岛州普罗维登斯。集团旗下拥有公民银行（Citizens Bank, N.A.），业务覆盖美国康涅狄格、特拉华、佛罗里达等十余个州及华盛顿哥伦比亚特区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CZFS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.6M
营收增速更快
RGNX
高出30.0%
13.0%
净利率更高
CZFS
高出256.7%
-221.3%
自由现金流更多
CZFS
多$88.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
6.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.6M | $30.3M |
| 净利润 | $10.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 44.2% | -190.0% |
| 净利率 | 35.4% | -221.3% |
| 营收同比 | 13.0% | 43.0% |
| 净利润同比 | 31.3% | -31.2% |
| 每股收益（稀释后） | $2.17 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CZFSRGNX
| Q4 25 | $29.6M | $30.3M | ||
| Q3 25 | $29.0M | $29.7M | ||
| Q2 25 | $27.3M | $21.4M | ||
| Q1 25 | $26.4M | $89.0M | ||
| Q4 24 | $26.2M | $21.2M | ||
| Q3 24 | $25.1M | $24.2M | ||
| Q2 24 | $24.6M | $22.3M | ||
| Q1 24 | $25.9M | $15.6M |
净利润CZFSRGNX
| Q4 25 | $10.5M | $-67.1M | ||
| Q3 25 | $10.0M | $-61.9M | ||
| Q2 25 | $8.5M | $-70.9M | ||
| Q1 25 | $7.6M | $6.1M | ||
| Q4 24 | $8.0M | $-51.2M | ||
| Q3 24 | $7.5M | $-59.6M | ||
| Q2 24 | $5.3M | $-53.0M | ||
| Q1 24 | $7.0M | $-63.3M |
毛利率CZFSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CZFSRGNX
| Q4 25 | 44.2% | -190.0% | ||
| Q3 25 | 42.6% | -176.3% | ||
| Q2 25 | 38.1% | -296.3% | ||
| Q1 25 | 35.5% | 13.6% | ||
| Q4 24 | 37.2% | -242.1% | ||
| Q3 24 | 36.9% | -256.6% | ||
| Q2 24 | 25.9% | -251.3% | ||
| Q1 24 | 32.8% | -408.8% |
净利率CZFSRGNX
| Q4 25 | 35.4% | -221.3% | ||
| Q3 25 | 34.5% | -208.3% | ||
| Q2 25 | 31.0% | -331.8% | ||
| Q1 25 | 28.8% | 6.8% | ||
| Q4 24 | 30.5% | -241.3% | ||
| Q3 24 | 30.0% | -246.3% | ||
| Q2 24 | 21.4% | -237.7% | ||
| Q1 24 | 27.1% | -405.4% |
每股收益（稀释后）CZFSRGNX
| Q4 25 | $2.17 | $-1.30 | ||
| Q3 25 | $2.09 | $-1.20 | ||
| Q2 25 | $1.76 | $-1.38 | ||
| Q1 25 | $1.60 | $0.12 | ||
| Q4 24 | $1.64 | $-0.99 | ||
| Q3 24 | $1.57 | $-1.17 | ||
| Q2 24 | $1.10 | $-1.05 | ||
| Q1 24 | $1.48 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $338.1M | $102.7M |
| 总资产 | $3.1B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CZFSRGNX
| Q4 25 | $34.3M | $230.1M | ||
| Q3 25 | $31.1M | $274.2M | ||
| Q2 25 | $49.5M | $323.3M | ||
| Q1 25 | $36.8M | $267.9M | ||
| Q4 24 | $42.2M | $234.7M | ||
| Q3 24 | $36.8M | $255.5M | ||
| Q2 24 | $38.4M | $290.4M | ||
| Q1 24 | $29.6M | $338.7M |
股东权益CZFSRGNX
| Q4 25 | $338.1M | $102.7M | ||
| Q3 25 | $327.7M | $161.5M | ||
| Q2 25 | $313.7M | $213.7M | ||
| Q1 25 | $308.3M | $274.2M | ||
| Q4 24 | $299.7M | $259.7M | ||
| Q3 24 | $298.7M | $301.4M | ||
| Q2 24 | $286.5M | $348.3M | ||
| Q1 24 | $282.7M | $390.7M |
总资产CZFSRGNX
| Q4 25 | $3.1B | $453.0M | ||
| Q3 25 | $3.1B | $525.2M | ||
| Q2 25 | $3.0B | $581.0M | ||
| Q1 25 | $3.0B | $490.9M | ||
| Q4 24 | $3.0B | $466.0M | ||
| Q3 24 | $3.0B | $519.1M | ||
| Q2 24 | $2.9B | $569.4M | ||
| Q1 24 | $2.9B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $36.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $35.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 119.0% | -174.0% |
| 资本支出强度资本支出/营收 | 4.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $53.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CZFSRGNX
| Q4 25 | $36.5M | $-52.3M | ||
| Q3 25 | $2.9M | $-56.0M | ||
| Q2 25 | $6.0M | $-49.3M | ||
| Q1 25 | $10.9M | $33.6M | ||
| Q4 24 | $33.2M | $-31.6M | ||
| Q3 24 | $6.2M | $-40.5M | ||
| Q2 24 | $3.0M | $-45.5M | ||
| Q1 24 | $13.5M | $-55.5M |
自由现金流CZFSRGNX
| Q4 25 | $35.2M | $-52.8M | ||
| Q3 25 | $2.7M | $-56.5M | ||
| Q2 25 | $5.5M | $-49.7M | ||
| Q1 25 | $10.4M | $32.6M | ||
| Q4 24 | $31.9M | $-32.7M | ||
| Q3 24 | $5.6M | $-40.9M | ||
| Q2 24 | $2.9M | $-46.0M | ||
| Q1 24 | $13.4M | $-56.0M |
自由现金流率CZFSRGNX
| Q4 25 | 119.0% | -174.0% | ||
| Q3 25 | 9.4% | -189.9% | ||
| Q2 25 | 20.1% | -232.8% | ||
| Q1 25 | 39.2% | 36.6% | ||
| Q4 24 | 121.6% | -154.2% | ||
| Q3 24 | 22.3% | -168.9% | ||
| Q2 24 | 11.8% | -206.2% | ||
| Q1 24 | 51.5% | -358.5% |
资本支出强度CZFSRGNX
| Q4 25 | 4.4% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 5.0% | 5.1% | ||
| Q3 24 | 2.5% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率CZFSRGNX
| Q4 25 | 3.49× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 1.44× | 5.53× | ||
| Q4 24 | 4.16× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 1.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CZFS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
